Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 1015550 in idiopathic pulmonary fibrosis over 12 weeks
NL-OMON49255Phase 2Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing BI 1015550 with Placebo (2 arms). Primary endpoint: Change from baseline in forced vital capacity at 12 weeks. Started Feb 2021; status: active, not recruiting.
02
Drugs
nerandomilast
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NL-OMON49255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49255.